Categories
  Encyclosphere.org ENCYCLOREADER
  supported by EncyclosphereKSF

Eritoran

From HandWiki - Reading time: 3 min

Short description: Chemical compound
Eritoran
Eritoran free acid skeletal.svg
Clinical data
Other namesE 5564
Routes of
administration
Intravenous injection
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC66H126N2O19P2
Molar mass1313.677 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Eritoran is a synthetic lipid that inhibits the receptor TLR4. It was developed as a potential treatment for severe sepsis, an excessive inflammatory response to an infection. It failed a five year Phase III clinical trial, the results of which were published in 2013,[1][2] and as of 2014 was no longer being developed.[3]

It was being developed by the Japanese pharmaceutical company Eisai Co. and was administered intravenously as the sodium salt eritoran tetrasodium.[4]

TLR4 is part of the innate immune system and plays an important role in triggering defense against pathogens. Eritoran is similar in structure to the lipopolysaccharide lipid A - a part of bacteria that binds to TLR4 and activates TLR4, triggering a defense. Eritoran binds to TLR4 but blocks its activation.[1][4]

Lipid A as found in E. coli, a gram-negative bacterium[4]
Eritoran[4]

Too much signalling by TLR4 may be part of what causes cytokine storms and sepsis, but as of 2021 no drug that inhibits TLR4 has been shown to prevent or treat sepsis or cytokine storms in humans.[1]

References

  1. 1.0 1.1 1.2 "Targeting Toll-Like Receptors in Sepsis: From Bench to Clinical Trials". Antioxidants & Redox Signaling 35 (15): 1324–1339. November 2021. doi:10.1089/ars.2021.0005. PMID 33588628. 
  2. "Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial". JAMA 309 (11): 1154–1162. March 2013. doi:10.1001/jama.2013.2194. PMID 23512062. 
  3. "Strategies to improve drug development for sepsis". Nature Reviews. Drug Discovery 13 (10): 741–758. October 2014. doi:10.1038/nrd4368. PMID 25190187. open access
  4. 4.0 4.1 4.2 4.3 "Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies". Expert Opinion on Drug Metabolism & Toxicology 7 (4): 479–494. April 2011. doi:10.1517/17425255.2011.558190. PMID 21323610. 

Further reading




Licensed under CC BY-SA 3.0 | Source: https://handwiki.org/wiki/Chemistry:Eritoran
7 views | Status: cached on September 24 2024 04:41:36
↧ Download this article as ZWI file
Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF